Campylobacteriosis a single center experience : literature review and own research

• Autorzy: Pasternak, Gerard , Cieślak, Anna , Walkowiak, Mateusz , Borawski, Wojciech , Lewandowicz-Uszyńska, Aleksandra
• Języki publikacji: EN

Abstrakty

EN

Campylobacteriosis is the most common acute bacterial diarrheal disease in our population. It is caused by bacteria of the genus Campylobacter species whose prevalence in the environment and ease of transmission make these infections a serious epidemiological problem. Although the disease usually has a picture of mild self-limiting diarrhea in some cases there is a more severe course with the need for hospital care. Colonization by Campylobacter spp. also plays on of the main role in the pathogenesis of other diseases. The study was conducted using data from the records of 67 patients aged 3 months to 10 years hospitalized for acute diarrheal illness caused by Campylobacter spp. Microbiological culture yielded growth of C. coli in 14 cases and C. jejuni in 52 patients. The isolated pathogens showed significant antibiotic resistance variable depending on the bacterial strain. The least susceptibility to the drugs occurred with erythromycin and was mainly related to C jejuni. In 42 children it was necessary to implement antibiotic therapy during which azithromycin, amoxicillin with clavulanic acid, or Biseptol were used.

Słowa kluczowe

EN

Campylobacter spp; Campylobacteriosis; children; diarrhea

• Czasopismo: International Journal of Electronics and Telecommunications
• Rocznik: 2024
• Tom: Vol. 70, No. 2
• Strony: 285--291
• Opis fizyczny: Bibliogr. 43 poz., tab.

Twórcy

autor

Pasternak, Gerard

• 3rd Department and Clinic of Paediatrics, Immunology and Rheumatology of Developmental Age, Wroclaw Medical University, Wroclaw, Poland Department of Immunology and Paediatrics, Provincial Hospital J. Gromkowski, Wroclaw, Poland,

autor

Cieślak, Anna

• Department of Paediatrics, Provincial Hospital J. Gromkowski, Wroclaw, Poland,

autor

Walkowiak, Mateusz

• 3rd Department and Clinic of Paediatrics, Immunology and Rheumatology of Developmental Age, Wroclaw Medical University, Wroclaw, Poland Department of Immunology and Paediatrics, Provincial Hospital J. Gromkowski, Wroclaw, Poland,

autor

Borawski, Wojciech

• Department of Surgery, Wroclaw University of Environmental and Life Sciences, Wroclaw, Poland,

autor

Lewandowicz-Uszyńska, Aleksandra

• 3rd Department and Clinic of Paediatrics, Immunology and Rheumatology of Developmental Age, Wroclaw Medical University, Wroclaw, Poland,
• Department of Immunology and Paediatrics, Provincial Hospital J. Gromkowski, Wroclaw, Poland

Bibliografia

• [1] N. O. Kaakoush, N. Castaño-Rodríguez, H. M. Mitchell, and S. M. Man, “Global epidemiology of campylobacter infection,” Clinical microbiology reviews, vol. 28, no. 3, pp. 687-720, 2015.
• [2] R. Isabel, “Campylobacter jejuni bacteremia in a patient with asplenia and enteritis,” IDCases, vol. 17, p. e00555, 2019. [Online]. Available: https://doi.org/10.1016/j.idcr.2019.e00555.
• [3] E. F. S. Authority, E. C. for Disease Prevention, C. (EFSA, and ECDC), “The European Union summary report on trends and sources of zoonoses, zoonotic agents and food-borne outbreaks in 2017,” EFSA Journal, vol. 16, no. 12, Dec. 2018. [Online]. Available: https://data.europa.eu/doi/10.2903/j.efsa.2018.5500.
• [4] W. Snelling, M. Matsuda, J. Moore, and J. Dooley, “Campylobacter jejuni,” Letters in Applied Microbiology, vol. 41, no. 4, pp. 297-302, Oct. 2005. [Online]. Available: https://doi.org/10.1111/j.1472-765x.2005.01788.x.
• [5] K. T. Young, L. M. Davis, and V. J. DiRita, “Campylobacter jejuni: molecular biology and pathogenesis,” Nature Reviews Microbiology, vol. 5, no. 9, pp. 665-679, Sep. 2007. [Online]. Available: https://doi.org/10.1038/nrmicro1718.
• [6] S. Epps, R. Harvey, M. Hume, T. Phillips, R. Anderson, and D. Nisbet, “Foodborne campylobacter: Infections, metabolism, pathogenesis and reservoirs,” International Journal of Environmental Research and Public Health, vol. 10, no. 12, pp. 6292-6304, Nov. 2013. [Online]. Available: https://doi.org/10.3390/ijerph10126292.
• [7] M. AbuOun, G. Manning, S. A. Cawthraw, A. Ridley, I. H. Ahmed, T. M. Wassenaar, and D. G. Newell, “Cytolethal distending toxin (CDT)-negative icampylobacter jejuni/i strains and anti-CDT neutralizing antibodies are induced during human infection but not during colonization in chickens,” Infection and Immunity, vol. 73, no. 5, pp. 3053-3062, May 2005. [Online]. Available: https://doi.org/10.1128/iai.73.5.3053-3062.2005.
• [8] C. Jäckel, J. Hammerl, and S. Hertwig, “Campylobacter phage isolation and characterization: What we have learned so far,” Methods and Protocols, vol. 2, no. 1, p. 18, Feb. 2019. [Online]. Available: https://doi.org/10.3390/mps2010018.
• [9] E. Acke, “Campylobacteriosis in dogs and cats: a review,” New Zealand veterinary journal, vol. 66, no. 5, pp. 221-228, 2018.
• [10] E. Acke, K. McGill, O. Golden, B. R. Jones, S. Fanning, and P. Whyte, “Prevalence of thermophilic icampylobacter/i species in household cats and dogs in Ireland,” Veterinary Record, vol. 164, no. 2, pp. 44-47, Jan. 2009. [Online]. Available: https://doi.org/10.1136/vr.164.2.44.
• [11] K. Bojanić, “Campylobacter species in dogs and cats and significance to public health in new zealand,” Ph.D. dissertation, PhD thesis, 2017.
• [12] M. Li, A. H. Havelaar, S. Hoffmann, T. Hald, M. D. Kirk, P. R. Torgerson, and B. Devleesschauwer, “Global disease burden of pathogens in animal source foods, 2010,” PLOS ONE, vol. 14, no. 6, p. e0216545, Jun. 2019. [Online]. Available: https://doi.org/10.1371/journal.pone.0216545.
• [13] S. Hoffmann, B. Devleesschauwer, W. Aspinall, R. Cooke, T. Corrigan, A. Havelaar, F. Angulo, H. Gibb, M. Kirk, R. Lake et al., “Attribution of global foodborne disease to specific foods: Findings from a world health organization structured expert elicitation,” PloS one, vol. 12, no. 9, p. e0183641, 2017.
• [14] T. Luangtongkum, B. Jeon, J. Han, P. Plummer, C. M. Logue, and Q. Zhang, “Antibiotic resistance in icampylobacter/i: emergence, transmission and persistence,” Future Microbiology, vol. 4, no. 2, pp. 189-200, Mar. 2009. [Online]. Available: https://doi.org/10.2217/17460913.4.2.189.
• [15] R. E. Black, M. M. Levine, M. L. Clements, T. P. Hughes, and M. J. Blaser, “Experimental campylobacter jejuni infection in humans,” Journal of infectious diseases, vol. 157, no. 3, pp. 472-479, 1988.
• [16] N. Rokosz, W. Rastawicki, and T. Wołkowicz, “Microbiological diagnosis of infections caused by campylobacter jejuni and campylobacter coli in humans,” Postępy Higieny i Medycyny Doświadczalnej, vol. 68, pp. 48-56, Jan. 2014. [Online]. Available: https://doi.org/10.5604/17322693.1086079.
• [17] C. Pigrau, R. Bartolome, B. Almirante, A.-M. Planes, J. Gavalda, and A. Pahissa, “Bacteremia due to campylobacter species: clinical findings and antimicrobial susceptibility patterns,” Clinical Infectious Diseases, vol. 25, no. 6, pp. 1414-1420, 1997.
• [18] C. Pigrau, R. Bartolome, B. Almirante, A.-M. Planes, J. Gavalda, and A. Pahissa, “Bacteremia due to campylobacter species: Clinical findings and antimicrobial susceptibility patterns,” Clinical Infectious Diseases, vol. 25, no. 6, pp. 1414-1420, Dec. 1997. [Online]. Available: https://doi.org/10.1086/516127.
• [19] S. M. Man, “The clinical importance of emerging campylobacter species,” Nature Reviews Gastroenterology &amp Hepatology, vol. 8, no. 12, pp. 669-685, Oct. 2011. [Online]. Available: https://doi.org/10.1038/nrgastro.2011.191.
• [20] S. Ben-Shimol, A. Carmi, and D. Greenberg, “Demographic and clinical characteristics of campylobacter bacteremia in children with and without predisposing factors,” Pediatric Infectious Disease Journal, vol. 32, no. 11, pp. e414-e418, Nov. 2013. [Online]. Available: https://doi.org/10.1097/inf.0b013e31829baae0.
• [21] J. Pacanowski, V. Lalande, K. Lacombe, C. Boudraa, P. Lesprit, P. Legrand, D. Trystram, N. Kassis, G. Arlet, J.-L. Mainardi et al., “Campylobacter bacteremia: clinical features and factors associated with fatal outcome,” Clinical Infectious Diseases, vol. 47, no. 6, pp. 790-796, 2008.
• [22] S. Macfarlane, E. Furrie, G. T. Macfarlane, and J. F. Dillon, “Microbial colonization of the upper gastrointestinal tract in patients with barrett's esophagus,” Clinical Infectious Diseases, vol. 45, no. 1, pp. 29-38, Jul. 2007. [Online]. Available: https://doi.org/10.1086/518578.
• [23] K. L. Blackett, S. S. Siddhi, S. Cleary, H. Steed, M. H. Miller, S. Macfarlane, G. T. Macfarlane, and J. F. Dillon, “Oesophageal bacterial biofilm changes in gastro-oesophageal reflux disease, barrett's and oesophageal carcinoma: association or causality?” Alimentary Pharmacology &amp Therapeutics, vol. 37, no. 11, pp. 1084-1092, Apr. 2013. [Online]. Available: https://doi.org/10.1111/apt.12317.
• [24] P. Macuch and A. Tanner, “Campylobacter species in health, gingivitis, and periodontitis,” Journal of Dental Research, vol. 79, no. 2, pp. 785-792, Feb. 2000. [Online]. Available: https://doi.org/10.1177/00220345000790021301.
• [25] K. O. Gradel, H. L. Nielsen, H. C. Schønheyder, T. Ejlertsen, B. Kristensen, and H. Nielsen, “Increased short-and long-term risk of inflammatory bowel disease after salmonella or campylobacter gastroenteritis,” Gastroenterology, vol. 137, no. 2, pp. 495-501, 2009.
• [26] L. Zhang, S. M. Man, A. S. Day, S. T. Leach, D. A. Lemberg, S. Dutt, M. Stormon, A. Otley, E. V. O’Loughlin, A. Magoffin, P. H. Ng, and H. Mitchell, “Detection and isolation of Campylobacter species other than C. jejuni from children with Crohn’s disease,” J Clin Microbiol, vol. 47, no. 2, pp. 453-455, Feb 2009.
• [27] L. Zhang, V. Budiman, A. S. Day, H. Mitchell, D. A. Lemberg, S. M. Riordan, M. Grimm, S. T. Leach, and Y. Ismail, “Isolation and detection of campylobacter concisus from saliva of healthy individuals and patients with inflammatory bowel disease,” Journal of clinical microbiology, vol. 48, no. 8, pp. 2965-2967, 2010.
• [28] J. Tankovic, B. Burghoffer, and J. Petit, “R2084 frequent detection by real-time pcr of bacteria from the helicobacter and campylobacter genera in stool samples from inflammatory bowel disease patients.”
• [29] S. M. Man, L. Zhang, A. S. Day, S. T. Leach, D. A. Lemberg, and H. Mitchell, “Campylobacter concisus and other campylobacter species in children with newly diagnosed crohn’s disease,” Inflammatory bowel diseases, vol. 16, no. 6, pp. 1008-1016, 2010.
• [30] V. Mahendran, S. M. Riordan, M. C. Grimm, T. A. T. Tran, J. Major, N. O. Kaakoush, H. Mitchell, and L. Zhang, “Prevalence of campylobacter species in adult crohn's disease and the preferential colonization sites of campylobacter species in the human intestine,” PLoS ONE, vol. 6, no. 9, p. e25417, Sep. 2011. [Online]. Available: https://doi.org/10.1371/journal.pone.0025417.
• [31] R. Hansen, S. H. Berry, I. Mukhopadhya, J. M. Thomson, K. A. Saunders, C. E. Nicholl, W. M. Bisset, S. Loganathan, G. Mahdi, D. Kastner-Cole, A. R. Barclay, J. Bishop, D. M. Flynn, P. McGrogan, R. K. Russell, E. M. El-Omar, and G. L. Hold, “The microaerophilic microbiota of de-novo paediatric inflammatory bowel disease: The BISCUIT study,” PLoS ONE, vol. 8, no. 3, p. e58825, Mar. 2013. [Online]. Available: https://doi.org/10.1371/journal.pone.0058825.
• [32] I. Mukhopadhya, J. M. Thomson, R. Hansen, S. H. Berry, E. M. El-Omar, and G. L. Hold, “Detection of campylobacter concisus and other campylobacter species in colonic biopsies from adults with ulcerative colitis,” PLoS ONE, vol. 6, no. 6, p. e21490, Jun. 2011. [Online]. Available: https://doi.org/10.1371/journal.pone.0021490.
• [33] S. P. Dunlop, D. Jenkins, K. R. Neal, and R. C. Spiller, “Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS,” Gastroenterology, vol. 125, no. 6, pp. 1651-1659, Dec. 2003. [Online]. Available: https: //doi.org/10.1053/j.gastro.2003.09.028.
• [34] J. Schwille-Kiuntke, P. Enck, C. Zendler, M. Krieg, A. V. Polster, S. Klosterhalfen, I. B. Autenrieth, S. Zipfel, and J.-S. Frick, “Postinfectious irritable bowel syndrome: follow-up of a patient cohort of confirmed cases of bacterial infection with salmonella or campylobacter,” Neurogastroenterology &amp Motility, vol. 23, no. 11, pp. e479-e488, Aug. 2011. [Online]. Available: https://doi.org/10.1111/j.1365-2982.2011.01779.x.
• [35] R. Moss-Morris and M. Spence, “To “lump” or to “split” the functional somatic syndromes: Can infectious and emotional risk factors differentiate between the onset of chronic fatigue syndrome and irritable bowel syndrome?” Psychosomatic Medicine, vol. 68, no. 3, pp. 463-469, May 2006. [Online]. Available: https://doi.org/10.1097/01.psy.0000221384.07521.05
• [36] W. H. Organization et al., WHO estimates of the global burden of foodborne diseases: foodborne disease burden epidemiology reference group 2007-2015. World Health Organization, 2015.
• [37] D. K. J. S. S. Wardak, U. Duda, “Pałeczki campylobacter jako dominujacy etiologiczny czynnik bakteryjnego zakażenia przewodu pokarmowego ludzi na przykładzie wybranego regionu polski [campylobacter spp. as a leading cause of human bacterial gastroenteritis in selected region of Poland],” Epidemiological Review Quarterly Journal of the National Institute of Public Health - NIH, vol. 63, no. 4, pp. 531–537, 2009.
• [38] D. Acheson and B. M. Allos, “Campylobacter jejuni infections: Update on emerging issues and trends,” Clinical Infectious Diseases, vol. 32, no. 8, pp. 1201-1206, Apr. 2001. [Online]. Available: https://doi.org/10.1086/319760.
• [39] J. P. Graham, J. J. Boland, and E. Silbergeld, “Growth promoting antibiotics in food animal production: an economic analysis,” Public health reports, vol. 122, no. 1, pp. 79-87, 2007.
• [40] A. H. T. Teh, S. M. Lee, and G. A. Dykes, “Growth in the presence of specific antibiotics induces biofilm formation by a campylobacter jejuni strain sensitive to them but not in resistant strains,” Journal of Global Antimicrobial Resistance, vol. 18, pp. 55-58, Sep. 2019. [Online]. Available: https://doi.org/10.1016/j.jgar.2019.05.020.
• [41] B. Feodoroff, A. Lauhio, P. Ellstrom, and H. Rautelin, “A nationwide study of campylobacter jejuni and campylobacter coli bacteremia in Finland over a 10-year period, 1998-2007, with special reference to clinical characteristics and antimicrobial susceptibility,” Clinical Infectious Diseases, vol. 53, no. 8, pp. e99-e106, Sep. 2011. [Online]. Available: https://doi.org/10.1093/cid/cir509.
• [42] B. Szczepańska, M. Andrzejewska, D. Śpica, and J. Klawe, “Campylobacter spp.- niedoceniany w Polsce czynnik etiologiczny zakażeń przewodu pokarmowego,” Problemy Higieny i Epidemiologii, vol. 95, no. 3, pp. 574-579, 2014.
• [43] A. E. Schnee and W. A. Petri, “Campylobacter jejuni and associated immune mechanisms,” Current Opinion in Infectious Diseases, vol. 30, no. 3, pp. 322-328, Jun. 2017. [Online]. Available: https://doi.org/10.1097/qco.0000000000000364.

Identyfikatory

DOI

10.24425/ijet.2024.149543